No Data
Jinling Pharmaceutical (000919.SZ): Magnesium sulfate injection has been approved for registration.
On December 11, 2023, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a "Pharmaceutical Registration Certificate" for magnesium sulfate injection issued by the National Medical Products Administration (Notification Number: 2024S30151). Magnesium sulfate injection can be used as an anticonvulsant for pregnancy-induced hypertension, to lower blood pressure, and to treat preeclampsia and eclampsia. Magnesium sulfate plays an important role in the prevention and treatment of eclampsia, hypertensive crises, asthma, and other diseases. Currently, China's "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)" ...
Jinling Pharmaceutical Completes Cancellation of Subsidiary
Jinling Pharmaceutical: Report for the third quarter of 2024
Jinling Pharmaceutical (000919.SZ): Intends to acquire a portion of shares of Xingong Fund and equity of non-cash distribution of Xingong Fund.
GeLongHui October 21st 丨 Jinling Pharmaceutical (000919.SZ) announced that, to build the company's global strategy of "medical and health care dual platform", improve the company's medical regional market layout, and at the same time resolve the same industry competition between Nanjing New Work Investment Group Co., Ltd. (referred to as "New Work Group") controlling Nanjing Meishan Hospital Co., Ltd. (referred to as "Nanjing Meishan Hospital") and the company, the company plans to acquire 164.7317 million yuan held by New Work Group South New Work Medical Industry Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Fund" or "New Work Fund") 28.46% of the contribution.
Unpleasant Surprises Could Be In Store For Jinling Pharmaceutical Company Limited's (SZSE:000919) Shares
The One-year Earnings Decline Is Not Helping Jinling Pharmaceutical's (SZSE:000919 Share Price, as Stock Falls Another 9.0% in Past Week
Investors One-year Losses Continue as Jinling Pharmaceutical (SZSE:000919) Dips a Further 10% This Week, Earnings Continue to Decline
